Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.90M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.01M
Average 0.05M
XLO Total Liabilities
Everything the company owes to creditors and other parties.
Xilio Therapeutics, Inc.NASDAQ: XLO
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 2.2% from a year ago
Total liabilities stood at $90.94M at the end of Q1 FY2026, down 2.2% from a year earlier and down 23.8% from the prior quarter. Over 3 fiscal years it compounded at +52.7% a year.
Context
- Total liabilities amounted to 55.6% of total assets at the end of Q1 FY2026, down 34.1 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -2.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 119.41M USD
- Year-over-year change
- +123.3%
- 4-year CAGR
- +34.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 119.41M | +123.3% |
| FY2024 | 2024-12-31 | 53.48M | +121.9% |
| FY2023 | 2023-12-31 | 24.1M | -28.1% |
| FY2022 | 2022-12-31 | 33.52M | -7.3% |
| FY2021 | 2021-12-31 | 36.17M | — |
Total Liabilities vs competitors
How XLO compares with its peers on the latest reported figures
- XLO's Mar 2026 total liabilities of $90.94M is the highest of the 4 companies compared; the peer median is $14.34M.
- Its year-over-year change of -2.2% is the 2nd highest of 4, against a peer median of -15.8%.
- Total liabilities amounts to 55.6% of total assets for XLO, versus a peer median of 24.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $90.94M | -2.2% | +52.7% | 55.6% | |
| Mar 2026 | $20.77M | -15.8% | -13.7% | 84.2% | |
OKUROnKure Therapeutics, Inc. | Mar 2026 | $14.34M | +55.3% | -56.2% | 7.2% |
| Jun 2026 | $9.86M | -77.6% | -2.7% | 24.5% | |
| Peer median (excluding XLO) | $14.34M | -15.8% | -13.7% | 24.5% | |
Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 198.05M | 120.39M | 44.7M | 55.29M | 137.53M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 4.46M | 4.11M | 3.42M | 4.94M | 2.5M |
| Total Current Assets | 202.52M | 124.5M | 48.13M | 60.23M | 145.03M |
| Property, Plant & Equipment (Net) | 13.9M | 12.84M | 11.2M | 9.06M | 7.85M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.55M | 1.56M | 0 | 1.78M | 1.81M |
| Tax Assets | 3.54M | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 90K | 267K | 1.6M | 0 | 0 |
| Total Non-current Assets | 19.08M | 14.67M | 12.8M | 10.84M | 9.66M |
| Total Assets | 221.6M | 139.17M | 60.93M | 71.08M | 154.69M |
| Account Payables | 3.14M | 3.13M | 1.05M | 2.57M | 3.17M |
| Short-term Debt | 883K | 6.67M | 3.32M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 13.52M | 40.02M |
| Other Current Liabilities | 3.61M | 82K | 6.9M | 4.21M | 5.73M |
| Total Current Liabilities | 12.78M | 21.12M | 15.96M | 27.26M | 56.27M |
| Long-term Debt | 9.63M | 3.17M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 3.54M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 19.26M | 0 |
| Other Non-current Liabilities | 0 | 45K | 0 | 0 | 57.53M |
| Total Non-current Liabilities | 23.39M | 12.4M | 8.14M | 26.22M | 63.14M |
| Total Liabilities | 36.17M | 33.52M | 24.1M | 53.48M | 119.41M |
| Common Stock | 3K | 3K | 3K | 5K | 36.89M |
| Retained Earnings | (160.89M) | (249.11M) | (325.51M) | (383.75M) | (418.79M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 417.17M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 185.43M | 105.65M | 36.83M | 17.6M | 35.27M |
| Total Debt | 20.74M | 19.94M | 11.46M | 8.14M | 6.95M |
| Net Debt | (177.32M) | (100.45M) | (33.25M) | (47.15M) | (130.58M) |
Xilio Therapeutics, Inc.
NASDAQ:XLO
Intrinsic Alpha fair value
Locked
Current Price
$7.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.